RxDoctor Payments DataLook up a doctor →

Candy Williams, APRN

Family · Tulsa, OKNPI 1124483482

Payments from drug & device makers

$21,644in general payments, 2019–2025

Across 1,044 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$2K
  • Madrigal Pharmaceuticals$2K
  • Regeneron Healthcare Solutions, Inc.$812
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$1,0805%
  • Food & beverage$20,32594%
  • Education$2391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,644 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$136,363
Medicare patients
729
Services billed
3,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab34$362,099
XifaxanRifaximin44$149,385
LinzessLinaclotide77$76,104
CreonLipase/Protease/Amylase17$56,035
ZenpepLipase/Protease/Amylase13$53,236
Dexlansoprazole DrDexlansoprazole38$13,692
ClenpiqSod Picosulf/Mag Ox/Citric Ac54$8,878
Mesalamine40$8,482
Omeprazole283$6,212
Colestipol Hcl50$5,699
Sucralfate51$5,536
Balsalazide Disodium31$5,059
Colesevelam Hcl34$4,090
Ursodiol21$3,918
Mesalamine ErMesalamine14$3,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,628$149,38544 claims
AbbVieLinzess, Creon$5,122$132,13994 claims
Aimmune Therapeutics, Inc.Zenpep$381$53,23613 claims
Ferring Pharmaceuticals Inc.Clenpiq$273$8,87854 claims
Braintree Laboratories, Inc.Sutab$243$2,93418 claims
SandozLansoprazole$14$1,47337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.

Other family in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →